Zoetis Posts Flat Q2 Revenue as Pet-Spending Softness Persists

Animal health's largest public company just posted a second consecutive soft quarter, and the numbers say the back half of the year has to work harder than the front half did.

Zoetis reported $2.5 billion in second-quarter revenue on August 6th — flat against a year ago and down 1% on an organic basis — after missing estimates and cutting guidance in the first quarter.

Zoetis reports flat Q2 revenue and $691M profit

Zoetis reported second-quarter 2026 revenue of $2.5 billion, essentially flat compared with the same period last year and down 1% on an organic operational basis. Net income came in at $691 million, with diluted earnings per share of $1.65.

The quarter follows a rougher start to the year. Zoetis's first-quarter 2026 results missed Wall Street's revenue and profit estimates and came with a cut to full-year guidance: the company lowered its 2026 outlook to $9.68 billion–$9.96 billion in revenue and $6.85–$7.00 in adjusted earnings per share, down from a prior range of $9.83 billion–$10.03 billion and $7.00–$7.10. That quarter's US companion-animal sales fell 11% year over year, which management attributed to fewer veterinary visits, extended dosing cycles, and pet owners shifting to lower-cost alternatives.

Two quarters into the year, Zoetis has now posted one revenue miss and one flat quarter against a guidance range it already cut once.

Why flat is a warning sign for animal health

For most consumer categories, flat revenue after a guidance cut wouldn't register as news. For Zoetis, it's the second data point in a pattern operators across animal health should be tracking: veterinary visit volume is softening, and it's showing up first in companion-animal spending — the same category driving growth for pet retailers, insurers, and diagnostics companies across the sector.

The mechanism matters more than the headline number. Zoetis's own commentary this year has pointed to pet owners stretching out dosing cycles and trading down to lower-cost alternatives rather than skipping treatment altogether — a demand-elasticity story, not a demand-collapse story. Add intensifying price competition in parasiticides, a category Zoetis has flagged this year as facing aggressive pricing and incentives from rivals, and the picture is less about pet owners disappearing than about a category where Zoetis's traditional pricing edge is eroding.

The rival's numbers make the same point from the other side. Elanco raised full-year guidance for the second straight quarter a day earlier, on roughly 10% revenue growth over the same three months Zoetis went flat. Two companies selling into the same clinics and moving in opposite directions points to share shifting between them, not to the whole category contracting.

Run the math against Zoetis's own guidance and the pressure gets concrete. First-half 2026 revenue totals roughly $4.8 billion — $2.3 billion in the first quarter plus $2.5 billion in the second. Hitting the low end of the company's full-year range, $9.68 billion, requires second-half revenue of about $4.88 billion, essentially flat sequential growth. Hitting the high end, $9.96 billion, requires $5.16 billion, a roughly 7.5% step up. After two quarters of misses and flat results, even the low end of Zoetis's own guidance now assumes the back half performs better than the front half did.

IDEXX, whose diagnostics revenue also tracks veterinary visit volume, posted the opposite result this week — beating Q2 estimates and raising guidance for the second time this year — a reminder that the softness Zoetis is describing isn't uniform across every corner of animal health.

Whether Zoetis adjusts guidance again this fall

Zoetis's next real test comes with third-quarter results, typically reported in early November, when the market finds out whether the sequential improvement its own guidance now requires actually shows up. A repeat of this year's pattern — another quarter of flat-to-negative organic growth — would put real pressure on management to cut guidance a second time.

Watch two things in the meantime. First, whether Zoetis's companion-animal portfolio outside the pressured categories can pick up enough share to offset the softness management has already flagged. Second, whether the international growth that offset US weakness in the first quarter — up 17% to $1.1 billion, with companion-animal sales abroad up 10% — continued at a similar pace, since a slowdown there would remove the one lever that's been working.

For the broader animal-health and pet-retail sector, Zoetis's results function as an early read on veterinary spending overall. If the category's largest, most diversified player needs a stronger back half just to hit an already-lowered bar, smaller operators selling into the same channel should plan for a tougher back half than they might otherwise expect.

Source: Zoetis via Business Wire